Maintenance Treatment for Type 1 Autoimmune Pancreatitis:
Effectiveness and Development of the PrescrAIP Relapse
Prediction Model

J 2026

Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model

LANZILLOTTA, Marco; Peter MACINGA; Jakob L POULSEN; Olof VINGE-HOLMQUIST; A Fatih DEMIRCI et al.

Základní údaje

Originální název

Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model

Autoři

LANZILLOTTA, Marco; Peter MACINGA; Jakob L POULSEN; Olof VINGE-HOLMQUIST; A Fatih DEMIRCI; Matteo TACELLI; Johanna BACKHUS; Hana ALGÜL; Clémence DESCOURVIERES; Mariia KIRIUKOVA; Elisabetta GONI; Marcus HOLLENBACH; Rainer C MIKSCH; Lumír KUNOVSKÝ; Miroslav VUJASINOVIC; Sara NIKOLIC; Luke DICKERSON; Michael HIRTH; Markus F NEURATH; Malte ZUMBLICK; Josephine VILA; Mustafa JALAL; Georg BEYER; Fabian FROST; Silvia CARRARA; Zdeněk KALA; Petr JABANDŽIEV; Gurhan SISMAN; Filiz AKYUZ; Gabriele CAPURSO; Massimo FALCONI; Alexander ARLT; Frank P VLEGGAAR; Luca BARRESI; Bill GREENHALF; László CZAKÓ; Peter HEGYI; Andrew HOPPER; Manu K NAYAR; Thomas M GRESS; Francesco VITALI; Alexander SCHNEIDER; Chris M HALLORAN; Jan TRNA; Alexey V OKHLOBYSTIN; Lorenzo DAGNA; Djuna L CAHEN; Dmitry BORDIN; Vinciane REBOURS; Julia MAYERLE; Alisan KAHRAMAN; Sebastian RASCH; Emma CULVER; Alexander KLEGER; Emma MARTÍNEZ-MONEO; Tomas HUCL; Søren S OLESEN; Marco J BRUNO; Ulrich BEUERS; Emanuel DELLA-TORRE; J Matthias LÖHR; Jonas ROSENDAHL a Kasper A OVERBEEK

Vydání

Clinical Gastroenterology and Hepatology, New York, Elsevier, 2026, 1542-3565

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30219 Gastroenterology and hepatology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 12.000 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

type 1 autoimmune pancreatitis; maintenance therapy; relapse prediction; PrescrAIP model; treatment effectiveness

Štítky

14110223, 14110317, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 6. 2026 10:20, Mgr. Tereza Miškechová

Anotace

V originále

Background & Aims Type 1 autoimmune pancreatitis (AIP) is a relapsing remitting disorder that often requires multiple treatment courses. Our aims were to assess the efficacy of maintenance treatment in preventing relapse and to develop the PrescrAIP risk score predicting relapse risk and the benefit of maintenance treatment. Methods We retrospectively analyzed patients meeting international diagnostic criteria for type 1 AIP who reached partial or complete remission after initial treatment. The primary outcome was disease relapse, defined as recurrence of symptoms and/or radiologic findings. We developed a multivariable prediction model using Cox proportional hazards regression, performed internal and internal-external validation, and built a predictive nomogram. Results We included 577 patients (68% male). During a median follow-up of 34 months (interquartile range, 13–69 months), we observed 154 relapses. The overall 3-year relapse risk was 28% (95% confidence interval [CI], 24%–32%), lower in patients receiving maintenance treatment than in those without (22% vs 35%; P < .001). The final PrescrAIP model incorporated protective factors (maintenance treatment, prior surgery, focal mass, female sex) and risk factors (biliary involvement, other organ involvement, IgG4 elevation, allergy, jaundice, acute pancreatitis). The model showed moderate discrimination (Concordance index, 0.69) and good calibration. Internal-external validation yielded Concordance index values ranging from 0.64 to 0.71. Maintenance treatment significantly reduced relapse in patients with a PrescrAIP score >155, but not in those with lower scores. Conclusion Maintenance therapy reduced relapse only in patients at high relapse risk. Once externally validated, the PrescrAIP score may guide personalized maintenance treatment decisions.

Citovat

@article{2559311,
   author = {Lanzillotta, Marco and Macinga, Peter and Poulsen, Jakob L and VingeandHolmquist, Olof and Demirci, A Fatih and Tacelli, Matteo and Backhus, Johanna and Algül, Hana and Descourvieres, Clémence and Kiriukova, Mariia and Goni, Elisabetta and Hollenbach, Marcus and Miksch, Rainer C and Kunovský, Lumír and Vujasinovic, Miroslav and Nikolic, Sara and Dickerson, Luke and Hirth, Michael and Neurath, Markus F and Zumblick, Malte and Vila, Josephine and Jalal, Mustafa and Beyer, Georg and Frost, Fabian and Carrara, Silvia and Kala, Zdeněk and Jabandžiev, Petr and Sisman, Gurhan and Akyuz, Filiz and Capurso, Gabriele and Falconi, Massimo and Arlt, Alexander and Vleggaar, Frank P and Barresi, Luca and Greenhalf, Bill and Czakó, László and Hegyi, Peter and Hopper, Andrew and Nayar, Manu K and Gress, Thomas M and Vitali, Francesco and Schneider, Alexander and Halloran, Chris M and Trna, Jan and Okhlobystin, Alexey V and Dagna, Lorenzo and Cahen, Djuna L and Bordin, Dmitry and Rebours, Vinciane and Mayerle, Julia and Kahraman, Alisan and Rasch, Sebastian and Culver, Emma and Kleger, Alexander and MartínezandMoneo, Emma and Hucl, Tomas and Olesen, Søren S and Bruno, Marco J and Beuers, Ulrich and DellaandTorre, Emanuel and Löhr, J Matthias and Rosendahl, Jonas and Overbeek, Kasper A},
   article_location = {New York},
   article_number = {5},
   doi = {https://doi.org/10.1016/j.cgh.2025.09.005},
   keywords = {type 1 autoimmune pancreatitis; maintenance therapy; relapse prediction; PrescrAIP model; treatment effectiveness},
   language = {eng},
   issn = {1542-3565},
   journal = {Clinical Gastroenterology and Hepatology},
   title = {Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model},
   url = {https://www.sciencedirect.com/science/article/abs/pii/S1542356525007955},
   volume = {24},
   year = {2026}
}

TY  - JOUR
ID  - 2559311
AU  - Lanzillotta, Marco - Macinga, Peter - Poulsen, Jakob L - Vinge-Holmquist, Olof - Demirci, A Fatih - Tacelli, Matteo - Backhus, Johanna - Algül, Hana - Descourvieres, Clémence - Kiriukova, Mariia - Goni, Elisabetta - Hollenbach, Marcus - Miksch, Rainer C - Kunovský, Lumír - Vujasinovic, Miroslav - Nikolic, Sara - Dickerson, Luke - Hirth, Michael - Neurath, Markus F - Zumblick, Malte - Vila, Josephine - Jalal, Mustafa - Beyer, Georg - Frost, Fabian - Carrara, Silvia - Kala, Zdeněk - Jabandžiev, Petr - Sisman, Gurhan - Akyuz, Filiz - Capurso, Gabriele - Falconi, Massimo - Arlt, Alexander - Vleggaar, Frank P - Barresi, Luca - Greenhalf, Bill - Czakó, László - Hegyi, Peter - Hopper, Andrew - Nayar, Manu K - Gress, Thomas M - Vitali, Francesco - Schneider, Alexander - Halloran, Chris M - Trna, Jan - Okhlobystin, Alexey V - Dagna, Lorenzo - Cahen, Djuna L - Bordin, Dmitry - Rebours, Vinciane - Mayerle, Julia - Kahraman, Alisan - Rasch, Sebastian - Culver, Emma - Kleger, Alexander - Martínez-Moneo, Emma - Hucl, Tomas - Olesen, Søren S - Bruno, Marco J - Beuers, Ulrich - Della-Torre, Emanuel - Löhr, J Matthias - Rosendahl, Jonas - Overbeek, Kasper A
PY  - 2026
TI  - Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model
JF  - Clinical Gastroenterology and Hepatology
VL  - 24
IS  - 5
SP  - 1321-1331
EP  - 1321-1331
PB  - Elsevier
SN  - 15423565
KW  - type 1 autoimmune pancreatitis
KW  - maintenance therapy
KW  - relapse prediction
KW  - PrescrAIP model
KW  - treatment effectiveness
UR  - https://www.sciencedirect.com/science/article/abs/pii/S1542356525007955
N2  - Background & Aims Type 1 autoimmune pancreatitis (AIP) is a relapsing remitting disorder that often requires multiple treatment courses. Our aims were to assess the efficacy of maintenance treatment in preventing relapse and to develop the PrescrAIP risk score predicting relapse risk and the benefit of maintenance treatment. Methods We retrospectively analyzed patients meeting international diagnostic criteria for type 1 AIP who reached partial or complete remission after initial treatment. The primary outcome was disease relapse, defined as recurrence of symptoms and/or radiologic findings. We developed a multivariable prediction model using Cox proportional hazards regression, performed internal and internal-external validation, and built a predictive nomogram. Results We included 577 patients (68% male). During a median follow-up of 34 months (interquartile range, 13–69 months), we observed 154 relapses. The overall 3-year relapse risk was 28% (95% confidence interval [CI], 24%–32%), lower in patients receiving maintenance treatment than in those without (22% vs 35%; P < .001). The final PrescrAIP model incorporated protective factors (maintenance treatment, prior surgery, focal mass, female sex) and risk factors (biliary involvement, other organ involvement, IgG4 elevation, allergy, jaundice, acute pancreatitis). The model showed moderate discrimination (Concordance index, 0.69) and good calibration. Internal-external validation yielded Concordance index values ranging from 0.64 to 0.71. Maintenance treatment significantly reduced relapse in patients with a PrescrAIP score >155, but not in those with lower scores. Conclusion Maintenance therapy reduced relapse only in patients at high relapse risk. Once externally validated, the PrescrAIP score may guide personalized maintenance treatment decisions.
ER  -

Přehled o publikaci